Analysts say loss of Toprol XL patent a significant threat to AstraZeneca

Share this article:
AstraZeneca faces a significant risk of losing US patent protection on its top selling heart drug Toprol XL (metoprolol succinate), according to analysts from Deutsche Bank. The analysts estimate there is around a 40 percent chance AstraZeneca will lose a ruling on the drug, according to a report from Reuters today. AstraZeneca has maintained its expectation of exclusivity on Toprol XL to hold until Sept. 2007, when US patents expire. The challenges to Toprol XL patents come from KV Pharmaceutical, Andrx Corp. and Eon Labs, a unit of Novartis. Sales of Toprol XL are expected to total around $1.3 billion in 2005. Generic drug makers have also recently challenged AstraZeneca’s two biggest sellers, the anitulcerant Nexium (esomeprazole magnesium delayed-release capsules), and Seroquel (quetiapine fumarate) for schizophrenia. In November AstraZeneca filed a lawsuit against Ranbaxy Laboratories in an attempt to stop the Indian drug maker from launching a copycat version of its top-selling medicine Nexium. Also in November, AstraZeneca filed a lawsuit against Teva Pharmaceuticals for infringement of AstraZeneca's substance patent protecting Seroquel.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...